FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization -- Company also reports preliminary unaudited 2024 revenue of $701.0 million -- Parsippany, NJ., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate ...